Trial · NCT07601646
A Single-Arm, Dose Escalation of an Intraurethral Alprostadil Paste for Erectile Dysfunction
NCT07601646, Phase 2, Recruiting, Ryan Flannigan, MD
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Single-Arm, Dose Escalation of an Intraurethral Alprostadil Paste for Erectile Dysfunction. Trials, record NCT07601646. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07601646
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Single-Arm, Dose Escalation of an Intraurethral Alprostadil Paste for Erectile Dysfunction
- NCT number
- NCT07601646
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 83 participants, estimated
- Lead sponsor
- Ryan Flannigan, MD
- Conditions
- Erectile Dysfunction (ED), Erectile Dysfunctions, Erectile Function
- Interventions
- ST-04
- First posted
- 2026-05-22
- Last updated
- 2026-05-22
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in the Erectile Function Domain of the IIEF Questionnaire | From baseline to 1 month after start of the last dose level (Week 4, 8, 12 respectively) | The IIEF is a validated questionnaire assessing erectile function, with total scores ranging from 5 to 25; higher scores indicate better erectile function |
| Secondary | Change from Baseline in the Erectile Hardness Scale (EHS) | From baseline to the end of treatment at week 4, 8 or 12 respectively | The EHS is a self-reported assessment of penile hardness on a scale of 0 (no engorgement) to 4 (complete rigidity). |
| Secondary | Change from Baseline in the Sexual Encounter Profile (SEP) | From baseline to the end of treatment at week 4, 8 or 12 respectively | SEP is a log diary completed after each sexual attempt, providing information as to whether the erection was hard enough to penetrate (SEP 2), or whether it was maintained for completion (SEP 3). |
| Secondary | Percentage of Uses per Participant of ST-04 which Led to the Onset of Erection within up to 30 minutes of Application per Number of Intercourse Attempts | From baseline to the end of treatment at week 4, 8 or 12 respectively | Percentage of participants using ST-04 that could achieve an erection and/or penetrative intercourse within 30 minutes of application per number of intercourse attempts. |
| Secondary | Incidence and Severity of Adverse events | From baseline to the end of treatment at week 4, 8 or 12 respectively | Adverse events will be recorded at each follow-up visit and classified by type, severity, and relationship to the intervention. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07601646
GET https://conductscience.org/api/trials/v1/NCT07601646/registered